AnswersPublished18 sources
What Moderna and Merck’s Phase 3 melanoma vaccine trial found
In 1,137 patients with surgically removed high risk melanoma, intismeran plus Keytruda lowered the risk of recurrence or death by 42%; two year recurrence free survival was 82.2% versus 70.0%. Moderna shares fell 17.6% at the close after the data became public, despite the positive trial result; investor expectation...
Published byEdited with GPT-6 LunaImages generated with GPT Image 2
Research answer
Key takeaways
- In 1,137 patients with surgically removed high risk melanoma, intismeran plus Keytruda lowered the risk of recurrence or death by 42%; two year recurrence free survival was 82.2% versus 70.0%.
- Moderna shares fell 17.6% at the close after the data became public, despite the positive trial result; investor expectations and questions about the vaccine’s commercial reach shaped the reaction.
AI Prompt
openai.comCreate a landscape editorial hero image for this Studio Global article: What did the Phase 3 trial of Moderna and Merck’s personalized melanoma vaccine, intismeran autogene, added to Keytruda show in 1,137 patien. Article summary: The trial was a clinical success, while the stock decline reflected disappointment against high investor expectations—not evidence that the vaccine failed. Adding intismeran autogene to Keytruda significantly improved re. Topic tags: general, news, general web. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fake numbers
Moderna and Merck’s Phase 3 INTerpath-001 trial found that adding the personalized mRNA therapy intismeran autogene to Keytruda improved outcomes for people with high-risk melanoma removed by surgery. The combination reduced the risk of recurrence or death by 42% compared with Keytruda alone. That is an encouraging clinical result, but it does not establish an overall-survival benefit or show that the approach works in other cancers. 4
5
What the Phase 3 trial found
INTerpath-001 enrolled 1,137 people with completely resected stage IIB–IV melanoma. Participants received intismeran plus Keytruda or Keytruda alone. 4
7
At the primary analysis, after a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42% (hazard ratio 0.58; 95% confidence interval 0.45–0.75). It also reduced the risk of distant metastasis or death by 38%. 4
5
At two years, 82.2% of patients in the combination group were alive without melanoma recurrence, compared with 70.0% in the Keytruda-only group—a difference of 12.2 percentage points. 2
The 42% figure is a relative reduction in the hazard of recurrence or death. It is not a 42-percentage-point improvement, nor does it mean deaths alone fell by 42%. Recurrence-free survival and distant-metastasis outcomes are important, but they do not by themselves demonstrate that patients live longer overall. 2
4
The companies also reported a larger effect after six months: a prespecified sensitivity analysis found a 58% lower risk of recurrence or death after that point. This is a separate analysis from the primary overall result and should be read alongside it, not instead of it. 4
Why the findings drew attention
The trial showed a statistically significant improvement over Keytruda alone in a large Phase 3 study, supporting intismeran as a promising potential postoperative treatment. The therapy remains investigational, however, so a positive trial does not make it an established standard of care. 4
5
The results apply to the patients and cancer type studied: people with resected high-risk melanoma. They do not establish that intismeran will work in other tumor types. The reported median follow-up of 24.6 months also means longer-term durability and overall survival remain open questions. 4
5
8
Why Moderna shares fell after positive data
Moderna shares closed down 17.6% after falling more than 25% intraday, even as the companies reported positive Phase 3 results. The data followed a sharp run-up in the stock, and the market reaction reflected high expectations as well as uncertainty about the vaccine’s broader commercial potential—not evidence that the trial failed. 1
17
Some coverage compared the Phase 3 effect with stronger results from the earlier, smaller Phase 2 study. Investors also wanted evidence that the vaccine could have applications beyond melanoma; this trial did not answer that question. 8
The leak and what comes next
The findings surfaced online before their scheduled presentation at the European Society for Medical Oncology meeting. ESMO released the results early after the leak. 8
19
The results support further regulatory discussions, but approval is not established by these trial findings alone. The key unresolved questions include whether the benefit lasts over longer follow-up, whether it translates into longer overall survival, and whether the approach can prove useful beyond melanoma. 4
5
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
People also ask
What is the short answer to "What Moderna and Merck’s Phase 3 melanoma vaccine trial found"?
In 1,137 patients with surgically removed high risk melanoma, intismeran plus Keytruda lowered the risk of recurrence or death by 42%; two year recurrence free survival was 82.2% versus 70.0%.
What are the key points to validate first?
In 1,137 patients with surgically removed high risk melanoma, intismeran plus Keytruda lowered the risk of recurrence or death by 42%; two year recurrence free survival was 82.2% versus 70.0%. Moderna shares fell 17.6% at the close after the data became public, despite the positive trial result; investor expectations and questions about the vaccine’s commercial reach shaped the reaction.
Sources
merck.comMerck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium - Merck.com
ajmc.comMerck, Moderna Cancer Vaccine Cuts Melanoma ...
bostonglobe.comModerna, Merck cancer vaccine met key endpoints in melanoma ...
fiercebiotech.comAfter leak, Merck and Moderna post phase 3 cancer vaccine data early